stockrow
Friday 6 November 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024.
- Revenue
- +13.0%
- EPS
- +20.8%
- Free cash flow
- +77.7%
- Total debt
- +7.63%
Quarter to September 2026, against a year earlier
6.86
0.61
−8.17%
Follow EOLS
Alert me
Evolus, Inc. (EOLS) P/E ratio
Evolus, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 26 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TKNO Alpha Teknova, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| ACB Aurora Cannabis Inc. compare | n/m |
| EVO Evotec AG compare | n/m |
| TLRY Tilray Brands, Inc. compare | n/m |
| EOLS Evolus, Inc. | n/m |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 4.3× |
| KMDA Kamada Ltd. compare | 18.1× |
| COLL Collegium Pharmaceutical, Inc. compare | 20.5× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)